Brian Anthony DiCarlo MD

Oncology•Los Angeles, CA

Breast Cancer, Hematologic Oncology, Thoracic Cancer

Assistant Clinical Professor of Medicine UCLA David Geffen School of Medicine UCLA Health - San Luis Obispo

Join to View Full Profile

300 Stein PlazaSuite 420Los Angeles, CA 90095
Phone+1 310-825-5111
Fax+1 310-825-7245

Summary

San Luis Obispo

Our community Cancer Care (hematology oncology) practices allow for easier access to comprehensive cancer care services right in your neighborhood.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
State University of New York Downstate Medical Center College of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2006 - 2026
NY State Medical License 2003 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Mar 10
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

8 citations
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Jian Zhang, Nicholas P McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo
Breast Cancer Research. 2023-07-06
40 citations
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine McNamara, Jason J. Zoeller, Gregory R. Bean
Nature Communications. 2020-11-17
5 citations
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Zorawar S. Noor, Jonathan W. Goldman, William E. Lawler, Bijoy Telivala, Fadi Braiteh
Lung Cancer. 2019-09-01

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member